

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, G01N 33/50, A01K 67/027, A61K 38/17	A2	(11) International Publication Number: WO 00/18917 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/US99/22302 (22) International Filing Date: 27 September 1999 (27.09.99) (30) Priority Data: 60/101,862 25 September 1998 (25.09.98) US 09/405,035 24 September 1999 (24.09.99) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: BIERE, Anja, Leona; 1272 Wilder Street, Thousand Oaks, CA 91362 (US). CITRON, Martin; 1272 Wilder Street, Thousand Oaks, CA 91362 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: α -SYNUCLEIN SUPER-MUTANTS ACCELERATE α -SYNUCLEIN AGGREGATION (57) Abstract Parkinson's disease (PD) is a neurodegenerative disorder which is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major component of which are filaments consisting of α -synuclein. The present invention provides α -synuclein mutations which accelerate α -synuclein aggregation and can thus be utilized for transgenic animal production and generation of the first progressive PD model. Also provided is an <i>in vitro</i> aggregation assay which can be utilized to identify α -synuclein nucleation inhibitors for the treatment of PD.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

α -SYNUCLEIN SUPER-MUTANTS ACCELERATE
 α -SYNUCLEIN AGGREGATION

BACKGROUND OF THE INVENTION

5

Parkinson's disease (PD) is a progressive, degenerative neurologic disorder which usually occurs in late mid-life, and is the second most common neurodegenerative disorder, after Alzheimer's disease.

10 PD predominantly affects dopaminergic neurons in the nigrastriatal system but also several other regions of the brain, and is clinically characterized by bradykinesia, tremor, and rigidity.

Bradykinesia, a slowness or "poverty" of movement, slows the pace of such utilitarian activities as walking and eating, and also makes movements that were once second nature take on a ponderous and deliberate quality. Tremor is a shakiness that generally affects limbs that are not otherwise in motion. For those PD patients diagnosed at a relatively young age, tremor is reported as the most disabling symptom. Older patients say their greatest challenge is walking or keeping their balance. Rigidity is caused by the inability of muscles to relax as opposing muscle groups contract, causing tension which can produce aches and pains in the back, neck, shoulders, temples, or chest.

PD is pathologically characterized by nerve cell loss in the substantia nigra and by the presence of intracytoplasmic Lewy bodies. A presynaptic protein, called α -synuclein, has been detected in Lewy bodies and shown to be the major filamentous component in Lewy bodies in PD; Spillantini et al., *Proc. Natl. Acad. Sci.*, 95:6469-6473 (1998).

35 Synuclein was originally cloned and identified as a synaptic protein in torpedo; Maroteaux

- 2 -

- et al., *J. Neurosci.*, 8:2804-2815 (1988) and later bovine; Nakjo et al., *Eur. J. Biochem.*, 217:1057-1063 (1993), rat; Maroteaux et al., *Mol. Brain Res.*, 11:335-343 (1991), and human (precursor of the non-A β component of Alzheimer's disease amyloid(NACP)); Ueda et al., *Proc. Natl. Aca. Sci. USA*, 90:11282-11286 (1993). Subsequent studies showed that there are two types of synucleins, α and β , and NACP is analogous to α -synuclein; Iwai et al., *Neuron*, 14:467-475 (1994).
- 10 The function of α -synuclein is unknown, but two naturally occurring mutations in α -synuclein, A53T and A30P, have been linked to familial early-onset PD; Polymeropoulos, et al., *Science*, 276:2045-2047 (1997); Kruger et al., *Nat. Genet.*, 18:106-108 (1998).
- 15 Baba et al., *Am. J. Pathol.*, 152:879-884 (1998) reported data strongly implicating α -synuclein in the selective degeneration of neurons in sporadic PD. Baba et al. suggest that the mechanisms leading to the selective incorporation of α -synuclein into
- 20 Lewy bodies probably involve alterations in the metabolism of α -synuclein that render it insoluble and prone to aggregation. Baba et al. thus postulate that wild type α -synuclein probably plays a role in the pathogenesis of sporadic PD, and that the A53T
- 25 substitution in α -synuclein may augment the process.
- Conway et al., *Nature Medicine*, 4:1318-1320 (1998) then reported that the naturally occurring α -synuclein mutations, A53T and A30P, may promote PD pathogenesis by accelerating α -synuclein fibril
- 30 formation, which may be an early step in Lewy body formation. Conway et al. utilize an *in vitro* fibrillization assay; Harper et al., *Ann. Rev. Biochem.*, 66:385-407 (1997), and present data demonstrating that both mutant forms, at high

- 3 -

concentrations, form Lewy body-like fibrils and discrete spherical assemblies; most rapidly by the A53T mutant. Based on their findings, Conway et al. postulate that inhibiting α -synuclein fibrillization may be an effective therapeutic strategy against the disease. Conway et al. also state that the *in vitro* fibrillization assay may allow compound libraries to be screened to identify such α -synuclein fibrillization inhibitors.

Despite these reports and other extensive PD research conducted to date, there is still no known cure for PD. Deprenyl (selegiline), begun early in the disorder, can slow progression of the disease, and there is also evidence that "antioxidants" such as vitamin E and selenium may be of some benefit. There clearly exists the need for improved means of diagnosis and treatment of PD.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to address this need by providing artificial α -synuclein super-mutants which demonstrate accelerated aggregation as compared to naturally occurring mutants and which can be utilized for transgenic animal production, and subsequent generation of the first progressive PD model.

Also provided is an *in vitro* aggregation assay which can be used to evaluate α -synuclein super-mutants, and which can be formatted to allow for the high throughput screening for α -synuclein nucleation inhibitors for the treatment of PD.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts near UV CD spectra of wild type (--), A30P (. . .), A53T (....), and A30P/A53T (.....) α -synuclein in phosphate buffered saline.

Figure 2 depicts far UV CD spectra of wild type (--), A30P (. . .), A53T (....), and A30P/A53T (.....) α -synuclein in phosphate buffered saline.

Figure 3 depicts aggregate formation of wild type (■), A30P (O), A53T (◆), and A30P/A53T (▲) α -synuclein. Aggregate formation was analyzed by measuring the UV absorption at 280 nm of protein in solution after ultracentrifugation. Values are means \pm S.E. of three different solutions.

Figure 4 depicts the second derivative FTIR spectrum of the initial solution of wild type protein. The spectrum shows primary random coil when the α -synuclein is in its solution structure (1650 cm^{-1} band).

Figure 5 depicts the second derivative FTIR spectrum of the wild type α -synuclein aggregate. The spectrum shows the final antiparallel β -sheet structure present in the α -synuclein pellet (1629 cm^{-1} band).

Figure 6 depicts aggregate formation of wild type α -synuclein at 2 mg/mL as monitored by A_{280} of soluble material following ultracentrifugation. A nonseeded control incubation is shown (■) along with incubations containing preformed wild type α -synuclein

- 5 -

aggregate as seed. Seed concentrations, expressed as a percentage of the soluble α -synuclein amount, were 0.001% (\blacklozenge), 0.01% (\blacksquare), 0.1% (\triangle), 1% (O) and 10% (\diamond), respectively. Values shown are the average of triplicate incubations \pm S.E.

Figure 7 depicts aggregate formation of wild type (\blacksquare), A53T (\blacklozenge), E83Q/A90V (O), H50Y/A53T (\triangle) and H50T/A53T/A76T (\square) α -synuclein. Aggregate formation was analyzed by measuring the concentration (mg/mL) of soluble protein in solution after ultracentrifugation. Values are means \pm S.E. of three different solutions.

DETAILED DESCRIPTION OF THE INVENTION

The term "isolated polypeptide" refers to a polypeptide of the invention that is free from at least one contaminating polypeptide that is found in its natural environment, and preferably substantially free from any other contaminating mammalian polypeptides which would interfere with its therapeutic or diagnostic use.

To perform the studies of the present invention, human α -synuclein cDNA; Ueda et al., *Proc. Natl. Aca. Sci. USA*, 90:11282-11286 (1993) was cloned, and bacterial expression constructs generated for the wild type protein, the A53T mutant, the A30P mutant, a form containing both the A53T and A30P mutations, and various other mutant forms. The wild type α -synuclein protein sequence used as a template for production of the various mutants of the present invention is that found in SEQ ID NO:1.

To perform the analysis on the various α -synuclein proteins, an *in vitro* assay was designed to look specifically for instances of accelerated

α -synuclein aggregation. The assay generally comprises: concentrating the test sample to 2-7 mg/ml; sterile filtering the sample through 0.22 micron filters to remove any particulate matter; incubating the sample over a specified period of time at 37°C with defined agitation; centrifuging aliquots of the incubated samples at predetermined times; and analyzing the pellet and supernatant of the aliquoted sample using various conventional techniques.

When the various α -synuclein proteins of the prior art were tested in the assay of the present invention, it was demonstrated that wild type α -synuclein, the naturally occurring A53T mutant form, and the naturally occurring A30P mutant form of α -synuclein can spontaneously form fibrillar β -sheet aggregates. It was also observed that in a complete aggregation time course, α -synuclein aggregation is slow and displays a distinct lag phase. And, importantly, the naturally occurring α -synuclein mutants each showed a reduced lag phase with respect to wild type α -synuclein, and enhanced the aggregation tendency observed in the wild type protein. This is critical, because a pathogenesis model which can cover all known mutants plus the wild type situation is less likely to be based on non disease relevant effects. For example, in the Alzheimer's disease field the key evidence for the amyloid hypothesis is the finding that all known early onset familial Alzheimer's disease mutations have one common effect: they increase A β 42 production compared to the wild type; Hardy, J., *Trends Neurosci.*, 20:154-159 (1997).

We hypothesized that the accelerated aggregation observed with both naturally occurring α -synuclein mutants was due to an increased tendency

- 7 -

to assume the β -sheet conformation found in the aggregates. Thus, other mutations that would cause destabilization of the α -helix and stabilization of β -sheet would be predicted to aggregate faster than the wild type protein, possibly even faster than the naturally occurring mutants. In view of this hypothesis, various other mutants were designed and tested. The first such mutant was a A53T/A30P double mutant, and it was demonstrated that this double mutant aggregated faster than each of the naturally occurring mutants, although the phenomenon was not observed in every instance. We then used several secondary structure prediction algorithms to design other artificial super-mutants; looking specifically for mutations which might further destabilize α -helix and enhance stabilization of β -sheets, and thus further accelerate aggregation *in vitro*. Standard references which describe algorithms useful for the secondary structure prediction include e.g., Chou and Fasman, *Adv. in Enzymol.*, 47:45-148 (1978) and Garnier et al., *J. Mol. Biol.*, 120:97 (1978).

We believe that very rapidly aggregating mutant α -synuclein is critical for the successful generation of a transgenic model of Lewy body formation, which can then be utilized to see whether such mice develop Parkinsonian symptoms. There have been no reports to date of successful production of a transgenic model using the naturally occurring mutants of the prior art, likely due to the slow aggregation processes associated with those mutants.

Using the secondary structure prediction algorithms, three mutants, E83Q/A90V (SEQ ID NO:2), H50Y/A53T (SEQ ID NO:3), and H50T/A53T/A76T (SEQ ID NO:4), were designed and tested in the *in vitro* assay. In each instance, the mutants demonstrated enhanced aggregation, with the H50T/A53T/A76T mutant showing

- 8 -

the most dramatic effect. Each of these super-mutants were used for transgenic animal production with the goal of generating the first progressive Parkinson's disease model. It is, of course, envisioned that one
5 could design other artificial "super mutants" using these methods.

A transgenic non-human animal comprising a nucleic acid molecule encoding an α -synuclein mutant polypeptide is thus encompassed by the invention. The
10 α -synuclein mutant nucleic acid molecules are introduced into the animal in a manner that allows expression and increased levels of an α -synuclein mutant polypeptide, which may include increased circulating levels. The transgenic non-human animal
15 is preferably a mammal, and more preferably a rodent, such as a rat or a mouse.

Nonhuman transgenic animals that are harboring at least one copy of a transgene comprising a polynucleotide sequence which encodes an α -synuclein
20 super mutant polypeptide operably linked to a transcription regulatory sequence capable of producing expression of the α -synuclein supermutant polypeptide in the transgenic animal will be used as Lewy body disease models. The α -synuclein supermutant
25 polypeptide should be expressed in cells which normally express the naturally occurring endogenous α -synuclein gene.

Additionally, the *in vitro* system described herein can be readily adapted to high throughput
30 screening for compounds which block α -synuclein nucleation. Such inhibitors could be useful as PD therapeutics if aggregation of α -synuclein is a critical step in all forms of PD.

It is thus contemplated that the assays and mutants of the present invention provide the means to identify potential therapeutics for any disease involving Lewy bodies, e.g., dementia with Lewy
5 bodies, as well as any α -synuclein disorder, including those where α -synuclein is not in form of Lewy bodies, e.g., multiple system atrophy.

EXAMPLE 1

10

This example describes the cloning and bacterial expression of the wild type α -synuclein protein and various naturally occurring and artificial α -synuclein mutant forms.

15

A 536 basepair human α -synuclein cDNA was obtained by PCR amplification from an adult human brain cDNA library using primers corresponding to nucleotides 20-42 and 532-556, respectively, of the published sequence; Ueda et al., *Proc. Natl. Aca. Sci. USA*, 90:11282-11286 (1993). PCR based site directed
20 mutagenesis of this sequence was then used to generate the mutant forms A53T, A30P, A53T/A30P, E83Q/A90V, H50Y/A53T, and H50T/A53T/A76T. For bacterial expression all forms were amplified using the
25 following primers:

TGTGGTCTAGAAGGAGGAATAACATATGGATGTATTCATGAAAG
GTCTGTCAAAGGCCAAGGAGGGTGTGTG (SEQ ID NO:5)

and

30

GGGACCGCGGCTCGAGATTAGGCTTCAGGTTCTAGTCTTGATA
ACCTTCCTCA (SEQ ID NO:6)

to alter 3 codons near the 5' end and 1 codon near the 3' end to more highly utilized *E.coli* codons. The
35 resulting PCR products were digested with NdeI and XhoI and cloned into the *E.coli* expression vector

- 10 -

pAMG21; Lacey et al., *Cell*, 93:165-176 (1998). The correct DNA sequence of all constructs was confirmed by DNA sequencing. *E. coli* containing the various plasmids were induced and protein expressed using
5 standard fermentation conditions.

Example 2

This example describes the purification and
10 characterization of the various α -synuclein forms prepared in Example 1.

E. coli cell paste was homogenized in 20mM Tris, 100mM NaCl, pH 7.5, with protease inhibitor cocktail Complete (Boehringer Mannheim). Cells in
15 suspension were broken by passaging through a Microfluidizer and a clarified lysate supernatant was collected after centrifugation at 18,000 x g for 45 minutes. *E. coli* contaminating proteins were then acid precipitated by adjusting the pH of the lysate
20 supernatant to pH 3.5 using 10% (v/v) of acetic acid, stirring for 20-30 minutes, and then centrifuging the mixture for 1 hour at 27,000 x g. The pH of the resulting supernatant was then adjusted to pH 7.5 using 10% (v/v) of acetic acid, and the sample applied
25 to a Q-Sepharose Fast Flow column (Pharmacia) equilibrated in 20mM Tris, pH 7.5. The α -synuclein protein was then eluted from the column using a NaCl gradient from 0 to 300mM NaCl in 20mM Tris, pH 7.5. The α -synuclein containing fractions were identified
30 by SDS-PAGE and found to be >99% pure. The concentration of α -synuclein was determined by measuring absorbance at 280 nm and employing $\epsilon_{280}^{0.1\%}$ of 0.354, determined by using Genetics Computer Group software.

- 11 -

To address whether wild type α -synuclein, the naturally occurring A53T α -synuclein mutant, the naturally occurring A30P α -synuclein mutant and an artificial A30P/A53T α -synuclein double mutant differ in their conformation, circular dichroism (CD) and FTIR spectroscopy were performed on the samples. CD spectra were determined at 20°C on a Jasco J-715 Spectropolarimeter, using water jacketed cuvettes with a pathlength of either 0.01 cm (for the far UV region, 250-190 nm, secondary structure) or 1 cm (for the near UV region, 340-240 nm, tertiary structure). Molar ellipticity was calculated using the protein concentration determined as above, and a Mean Residue Weight of 103. Fresh samples of all proteins showed the natively unfolded structure previously described for the wild type protein; Weinreb et al., *Biochemistry*, 35:13709-13715 (1996), with identical near and far UV CD spectra (see Figures 1 and 2).

FTIR spectra of aqueous protein solutions were recorded at 25°C with a Nicolet Magna 550 Fourier transform infrared spectrometer, equipped with a DTGS detector. Protein solutions were prepared for infrared measurement in a sample cell (Spectra-Tech FT04-036) that employed CaF₂ windows separated by a 6 μ m spacer. The final protein spectrum was smoothed with a 7-point Savitsky-Golay smooth function to remove the white noise. Second-derivative spectra were calculated with the derivative function of the Nicolet Omnic software. To quantitate the secondary structure from the second derivative spectra, the spectra were inverted by multiplication by -1 and the curve fit (SpectraCalc Software from Galactic Industries) with Gaussian band profiles; Dong et al., *Biochemistry*, 31:9364-9370 (1992). The FTIR spectra of these molecules were also indistinguishable, and indicated that they contain

- 12 -

primarily random coil structure, with the induction of a small amount of helix (about 10%). This data confirms that the initial conformation of the wild type and the mutants is identical.

5

EXAMPLE 3

This example describes the *in vitro* aggregation experiments first performed on the wild type α -synuclein, the naturally occurring A53T mutant, the naturally occurring A30P mutant, and the A30P/A53T mutant forms prepared in Example 2.

Purified samples of the four forms were concentrated to >7 mg/ml in Tris-buffered saline (20mM Tris, 200 mM NaCl, pH 7.5) (TBS) + 0.05% sodium azide and then sterile filtered through 0.22 micron filters to remove any particulate matter. Each of the filtrates was then adjusted to a final concentration in the range of ~7 mg/ml in TBS + 0.05% sodium azide and incubated over several days at room temperature, 4°C, and 37°C in parafilm sealed, 1.5 ml ultracentrifuge tubes (Beckman). During the time frame of the experiment, no aggregates formed when incubated at room temperature or at 4°C.

After incubation for several days at 37°C, all samples began to form insoluble aggregates that could be precipitated by ultracentrifugation. The aggregation proceeded until most of the material had fallen out of solution. At various time points, the 37°C samples were centrifuged at 100,000 x g for 10 minutes and the α -synuclein content of the supernatants analyzed by measuring their absorbance at 280 nm. The concentration of α -synuclein was then determined as described in Example 2 (supernatants of samples with concentrations 4 mg/ml or higher were first diluted 1:10 with TBS (11 μ l sample + 99 μ l

- 13 -

buffer; supernatants of samples at concentrations below 4 mg/ml were analyzed directly (100 μ l)). The nonused portion of all samples were vortexed for 30 seconds to resuspend pelleted material and then
5 allowed to continue incubation at 37°C. If the supernatant was analyzed neat, the 100 μ l aliquot used for absorbance measurements was returned to the original incubation tube which was then vortexed for 30 seconds and placed back at 37°C. Curve fits for
10 aggregation time courses (i.e. A_{280} vs. time) were drawn manually (see Figure 3).

It was observed that in a complete aggregation time course, α -synuclein aggregation is slow and displays a distinct lag phase. The lag phase
15 preceding α -synuclein fibril formation was indicative of a nucleation dependent polymerization and the fact that stirring or shaking dramatically increases the aggregation rate is also supportive of such a mechanism. It was also observed that the aggregate
20 formation was faster for the mutant forms than for the wild type, and the A53T and A30P/A53T mutations had a more dramatic effect than the A30P mutation. The lag time for formation of precipitable aggregates was about 280 hours for the wild type protein, 180 hours
25 for the A30P mutant, and only 100 hours for the A53T and A30P/A53T mutations.

At each time point tested, the soluble and insoluble materials were evaluated. The secondary structure of the protein that remained soluble was
30 analyzed by CD and found not to change for any of the proteins throughout the experiments. The structure of the protein that was in the pellet was analyzed by FTIR. Specifically, α -synuclein aggregates were centrifuged at 13,000 rpm for 10 minutes, spread on a
35 3M disposable IR card, air dried, and the infrared

- 14 -

spectra recorded. As Figure 4 clearly shows, aggregation and precipitation of α -synuclein is accompanied by a dramatic change in secondary structure, from the initial primarily random coil seen when the α -synuclein is in solution structure (1650 cm^{-1} band), to the final antiparallel β -sheet structure present in the α -synuclein pellet (1629 cm^{-1} band, Figure 5). This structure is commonly observed in protein aggregates. The spectra of the aggregate of all forms are indistinguishable. It was also observed that the loss of soluble material was paralleled by an increase in pellet size.

To address whether the precipitates contain only amorphous aggregates or distinct fibrillar structures, the precipitates were analyzed by electron and atomic force microscopy. Electron Microscopy analysis utilized Formvar coated 300mesh copper grids which were inverted over 20 μl drops of prepared α -synuclein aggregate suspensions for 10 minutes. The grids were then rinsed in ultrapure water to remove excess, nonadherent material and then allowed to dry at room temperature. The grids were placed sample down on 2% aqueous uranyl acetate for 30 minutes, rinsed in water and allowed to dry. The grids were examined at 120 kV and representative fields photographed at 45,000 diameters magnification on a Philips CM120 transmission electron microscope. Fibrils of the wild type and mutant proteins were readily detected in the precipitates by electron microscopy with positive staining. The diameter of the fibrils is around 12 nm.

Atomic Force Microscopy involved resuspension of the aggregated α -synuclein in PBS and vortexing for 10 seconds. 40 μl of this suspension was incubated on a circular piece of mica for about 3

- 15 -

minutes. Excess liquid was removed and the sample on the mica was then imaged under 40 μ l of PBS using a Digital Instruments Nanoscope III atomic force microscope. The probe used for imaging was an oxide-sharpened silicon nitride twin tip with a nominal
5 spring constant of 0.58 N/m. The image was obtained in "tapping mode" in fluid using a drive frequency of 8.67 kHz, a drive amplitude of 200 mV and a setpoint voltage of 0.252 Volts. Fluid phase atomic force
10 microscopy also clearly demonstrated the presence of fibrils in their native aqueous environment.

EXAMPLE 4

15 This example describes a study wherein the addition of exogenous aggregated α -synuclein functioning as nuclei (seeds) was examined for its ability to start elongation instantly and expedite aggregation.

20 Solutions of wild type α -synuclein or the A53T mutant at 7 mg/ml were incubated in TBS + 0.05% sodium azide at 37°C for 3 days with continuous shaking (high speed); under these conditions the equilibrium was reached. Critical concentrations were
25 then determined as described by Jarrett et al., *Biochemistry*, 32:4693-4697 (1993) by taking the samples and centrifuging for 10 minutes at 100,000 x g, collecting and filtering the supernatant through 0.22 micron filters for analysis by
30 quantitative amino acid analysis to determine protein content.

To perform amino acid analysis, samples were transferred to pyrolyzed glass vial inserts, dried and then transferred to a Water's Picotag reaction vial,
35 which contained 1 ml of a hydrolysis cocktail (6N hydrochloric acid, 0.05% phenol, 0.001%

- 16 -

β -mercaptoethanol). The reaction vial was then purged with nitrogen and then sealed under vacuum; hydrolysis took place at 110°C for 24 hours. The sample glass inserts were removed and dried, and the samples reconstituted in sample buffer containing the internal standard norleucine. Samples were analyzed on a Beckman 6300 Amino Acid Analyzer (sodium format). Specialized software was used to calculate concentrations from the observed amino acids and internal standard recoveries. The software calculates a correlation coefficient and an average percentage difference between the observed and theoretical number of residues. Reported seed concentrations are based on the amount of monomeric protein used, assuming complete aggregation of the starting material. The material was stored frozen at -20°C until needed.

Incubations of soluble α -synuclein at concentrations ranging from 2-7 mg/ml in TBS + 0.05% sodium azide, were spiked with various amounts of pre-formed α -synuclein aggregates to serve as nuclei for fibril formation. The final concentration of seed is reported as a percentage of the soluble α -synuclein in the incubation (e.g. a 2 mg/ml incubation seeded at a level of 10% contains 0.2 mg/ml seed). Loss of soluble α -synuclein is measured by A_{280} of soluble material following ultracentrifugation as described above.

The addition of mutant α -synuclein as seeds to aggregation-competent, supersaturated solutions of wild type α -synuclein bypasses the lag phase and causes rapid aggregation as shown in Figure 6 (open vs. filled symbols). Seed concentrations in the experiment ranged from 0.001% (\diamond) of the soluble α -synuclein amount up to 10% (\diamond) and it is instantly apparent that the aggregation rate of soluble

α -synuclein is controlled by the seed content in a dose dependent manner. Analyzing the data from Figure 6 as the time required to deplete 50% of the soluble starting material ($t_{1/2}$) allows a quantitative
5 comparison of the seeding efficiency. At 2 mg/ml under our aggregation conditions, unseeded wild type α -synuclein (n) aggregated with a half life of 18 days. With the seed content consisting of only 0.001% (\diamond) of the soluble α -synuclein, the $t_{1/2}$ already
10 decreased to 16 days. At 0.01% (\square) seed the $t_{1/2}$ was 11 days and seed concentrations of 0.1% (Δ), 1% (O) and 10% (\diamond) seed resulted in a further decrease of half lives to 7, 4 and 0.5 days, respectively.

These studies showed that α -synuclein
15 fibrillogenesis is a nucleation-dependent process that can be seeded by α -synuclein functioning as nuclei. These data lead us to predict that the Lewy bodies of familial PD patients with α -synuclein mutations will contain both the mutant and wild type protein.

20 It was also determined that the fibril growth follows first-order kinetics with respect to α -synuclein concentration, and wild type and mutant forms of α -synuclein do not differ in their critical concentrations. This data thus confirms that
25 α -synuclein aggregation fulfills all criteria of a nucleation-dependent polymerization process. In this regard, α -synuclein fibril formation resembles that of β -amyloid (A β) and paired helical filaments, two protein aggregates characteristic for Alzheimer's
30 disease. And, interestingly, because the critical concentrations of the wild type and mutant α -synuclein do not differ significantly, it suggests that differences in aggregation kinetics of α -synucleins

- 18 -

cannot be explained by differences in solubility, but rather are due to different nucleation rates. As such, α -synuclein nucleation appears to be the rate-limiting step for the formation of Lewy body

5 α -synuclein fibrils in PD.

EXAMPLE 5

This example describes the *in vitro*
10 aggregation experiments performed on the artificial H50Y/A53T mutant, the artificial E83Q/A90V mutant, and the artificial H50T/A53T/A76T mutant. The wild type α -synuclein and naturally occurring A53T mutant served as controls.

15 Purified samples of the five forms were concentrated to >7 mg/ml in Tris-buffered saline (20mM Tris, 200 mM NaCl, pH 7.5) (TBS) + 0.05% sodium azide and then sterile filtered through 0.22 micron filters to remove any particulate matter. Each of the
20 filtrates was then adjusted to a final concentration in the range of ~7 mg/ml in TBS + 0.05% sodium azide and incubated over several days at 37°C in parafilm sealed, 1.5 ml ultracentrifuge tubes (Beckman).

After incubation for several days at 37°C,
25 all samples began to form insoluble aggregates that could be precipitated by ultracentrifugation. The aggregation proceeded until most of the material had fallen out of solution. At various time points, the 37°C samples were centrifuged at 100,000 x g for 10
30 minutes and the α -synuclein content of the supernatants analyzed by measuring their absorbance at 280 nm. The concentration of α -synuclein was then determined as described in Example 2 (supernatants of samples with concentrations 4 mg/ml or higher were
35 first diluted 1:10 with TBS (11 μ l sample + 99 μ l

- 19 -

buffer; supernatants of samples at concentrations below 4 mg/ml were analyzed directly (100 μ l)). Curve fits for aggregation time courses (i.e. A_{280} vs. time) were drawn manually (see Figure 7).

5 It was observed that the aggregate formation_ was enhanced for the E83Q/A90V and H50Y/A53T mutants, even when compared to the A53T mutant. And, importantly, the aggregate formation was significantly enhanced for the H50T/A53T/A76T mutant.

10

EXAMPLE 6

 This example describes the use of the E83Q/A90V, H50Y/A53T, and H50T/A53T/A76T forms for
15 transgenic animal production.

 For the generation of transgenes, a SmaI fragment of α -synuclein cDNA containing the entire coding region was blunt-end ligated into a blunted XhoI site in exon 2 of the Thy-1 transgene expression
20 vector; Moechars et al., *EMBO JOURNAL.*, 15(6):1265-74, (1996). The transgenic animals were prepared using well known methods such as those described in U.S. Patent No 5,489,743 and PCT Publication No. WO94/28122, each of which is hereby incorporated by
25 reference in its entirety.

 The transgenic animals may be used for drug candidate screening. The impact of a drug candidate on the animal may be measured. For example, drug candidates may decrease expression of the α -synuclein
30 polypeptide gene. In certain embodiments, the amount of α -synuclein polypeptide or a fragment(s) that is produced may be measured after exposure of the animal to the drug candidate. In certain embodiments, one may detect the actual impact of the drug candidate on
35 the animal. For example, overexpression of a

- 20 -

particular gene may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease expression of the gene or its ability to prevent or

5 inhibit a pathological condition. In other examples, production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability

10 to decrease production of such a metabolic product or its ability to prevent or inhibit a pathological condition.

The foregoing descriptions of the specific

15 embodiments so fully reveal the general nature and applicability of the present invention that others can readily modify, adapt and/or optimize such specific embodiments for an assortment of assay methods using a variety of reagents and materials, without departing

20 from the present inventive concept. Any such modifications and adaptations are intended to be embraced within the meaning and range of equivalents of this invention.

- 21 -

Claims:

1. An isolated artificial α -synuclein mutant polypeptide which demonstrates accelerated aggregation as compared to naturally occurring α -synuclein mutant polypeptides.
2. A polypeptide of Claim 1, said polypeptide comprising the amino acid sequence selected from the group consisting of the amino acid sequence as set forth in at least one of SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.
3. An *in vitro* aggregation assay for evaluating α -synuclein mutants which demonstrate accelerated aggregation, said assay comprising the steps of:
 - (a) generating pure α -synuclein protein;
 - (b) incubating the α -synuclein solution with defined agitation;
 - (c) centrifuging aliquots of the incubated samples at predetermined times; and
 - (4) analyzing the pellet and the supernatant of the aliquoted samples using various conventional techniques.
4. A transgenic non-human mammal which has been genetically engineered to express the polypeptide of claim 1 in the brain.
5. An *in vitro* aggregation assay for high throughput screening for α -synuclein nucleation inhibitors, said assay comprising:
 - (a) generating a solution of α -synuclein or aggregation competent fragments of

- 22 -

α -synuclein or the mutant polypeptides
of Claim 1;

- 5 (b) incubating said solution with a
potential nucleation-affecting agent
under conditions that allow α -synuclein
aggregation in the absence of the
agent;
- (c) detecting the amount of aggregated
 α -synuclein; and
- 10 (d) assessing the effect of said agent on
the aggregation of α -synuclein.

6. The method of claim 5 wherein the
 α -synuclein or α -synuclein fragment is labeled
15 radioactively, enzymatically, fluorescently or
antigenically.

7. A method for treating, preventing, or
ameliorating PD, or related disorder, comprising
20 administering to a patient an effective amount of an
 α -synuclein nucleation-affecting agent identified
according to Claim 5.

FIGURE 1




FIGURE 2





FIGURE 3


FIGURE 4


FIGURE 5

FIGURE 6





FIGURE 7



SEQUENCE LISTING

<110> AMGEN INC.

<120> ALPHA-SYNUCLEIN SUPER-MUTANTS ACCELERATE
ALPHA-SYNUCLEIN AGGREGATION

<130> A-565

<140> NOT YET ASSIGNED

<141> 1999-09-24

<150> 60/101,862

<151> 1998-09-25

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 140

<212> PRT

<213> ADULT HUMAN BRAIN

<400> 1

Met	Asp	Val	Phe	Met	Lys	Gly	Leu	Ser	Lys	Ala	Lys	Glu	Gly	Val	Val
1				5					10					15	
Ala	Ala	Ala	Glu	Lys	Thr	Lys	Gln	Gly	Val	Ala	Glu	Ala	Ala	Gly	Lys
			20					25						30	
Thr	Lys	Glu	Gly	Val	Leu	Tyr	Val	Gly	Ser	Lys	Thr	Lys	Glu	Gly	Val
			35				40						45		
Val	His	Gly	Val	Ala	Thr	Val	Ala	Glu	Lys	Thr	Lys	Glu	Gln	Val	Thr
	50					55					60				
Asn	Val	Gly	Gly	Ala	Val	Val	Thr	Gly	Val	Thr	Ala	Val	Ala	Gln	Lys
65					70					75					80
Thr	Val	Glu	Gly	Ala	Gly	Ser	Ile	Ala	Ala	Ala	Thr	Gly	Phe	Val	Lys
				85					90						95
Lys	Asp	Gln	Leu	Gly	Lys	Asn	Glu	Glu	Gly	Ala	Pro	Gln	Glu	Gly	Ile
			100					105					110		
Leu	Glu	Asp	Met	Pro	Val	Asp	Pro	Asp	Asn	Glu	Ala	Tyr	Glu	Met	Pro
			115				120					125			
Ser	Glu	Glu	Gly	Tyr	Gln	Asp	Tyr	Glu	Pro	Glu	Ala				
	130					135					140				

<210> 2

<211> 140

<212> PRT

<213> ADULT HUMAN BRAIN

<400> 2

Met Asp Val Phe Met Lys Gly Leu Ser Lys Ala Lys Glu Gly Val Val

PCT/US99/22302

```
<210> 3
<211> 140
<212> PRT
<213> ADULT HUMAN BRAIN
```

```

<400> 3
Met Asp Val Phe Met Lys Gly Leu Ser Lys Ala Lys Glu Gly Val Val
  1          5          10          15

Ala Ala Ala Glu Lys Thr Lys Gln Gly Val Ala Glu Ala Ala Gly Lys
  20          25          30

Thr Lys Glu Gly Val Leu Tyr Val Gly Ser Lys Thr Lys Glu Gly Val
  35          40          45

Val Tyr Gly Val Thr Thr Val Ala Glu Lys Thr Lys Glu Gln Val Thr
  50          55          60

Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Ala Val Ala Gln Lys
  65          70          75          80

Thr Val Glu Gly Ala Gly Ser Ile Ala Ala Ala Thr Gly Phe Val Lys
  85          90          95

Lys Asp Gln Leu Gly Lys Asn Glu Glu Gly Ala' Pro Gln Glu Gly Ile
  100          105          110

Leu Glu Asp Met Pro Val Asp Pro Asp Asn Glu Ala Tyr Glu Met Pro
  115          120          125

Ser Glu Glu Gly Tyr Gln Asp Tyr Glu Pro Glu Ala
  130          135          140

```

<210> 4
 <211> 140
 <212> PRT
 <213> ADULT HUMAN BRAIN

<400> 4
 Met Asp Val Phe Met Lys Gly Leu Ser Lys Ala Lys Glu Gly Val Val
 1 5 10 15
 Ala Ala Ala Glu Lys Thr Lys Gln Gly Val Ala Glu Ala Ala Gly Lys
 20 25 30
 Thr Lys Glu Gly Val Leu Tyr Val Gly Ser Lys Thr Lys Glu Gly Val
 35 40 45
 Val Thr Gly Val Thr Thr Val Ala Glu Lys Thr Lys Glu Gln Val Thr
 50 55 60
 Asn Val Gly Gly Ala Val Val Thr Gly Val Thr Thr Val Ala Gln Lys
 65 70 75 80
 Thr Val Glu Gly Ala Gly Ser Ile Ala Ala Ala Thr Gly Phe Val Lys
 85 90 95
 Lys Asp Gln Leu Gly Lys Asn Glu Glu Gly Ala Pro Gln Glu Gly Ile
 100 105 110
 Leu Glu Asp Met Pro Val Asp Pro Asp Asn Glu Ala Tyr Glu Met Pro
 115 120 125
 Ser Glu Glu Gly Tyr Gln Asp Tyr Glu Pro Glu Ala
 130 135 140

<210> 5
 <211> 73
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 oligonucleotide

<400> 5
 tgtgtcttag aaggaggaat aacatatgga tgtattcatg aaaggtctgt caaaggccaa 60
 ggagggtggt gtg 73

<210> 6
 <211> 54
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 oligonucleotide

<400> 6
 gggaccgcgg ctcgagatta ggcttcaggt tcgtagtctt gataaccttc ctca 54

**CORRECTED
VERSION***

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, G01N 33/50, A01K 67/027, A61K 38/17	A3	(11) International Publication Number: WO 00/18917 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/US99/22302 (22) International Filing Date: 27 September 1999 (27.09.99) (30) Priority Data: 60/101,862 25 September 1998 (25.09.98) US 09/405,035 24 September 1999 (24.09.99) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: BIERE, Anja, Leona; 1272 Wilder Street, Thousand Oaks, CA 91362 (US). CITRON, Martin; 1272 Wilder Street, Thousand Oaks, CA 91362 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 2 November 2000 (02.11.00)	
(54) Title: α -SYNUCLEIN SUPER-MUTANTS ACCELERATE α -SYNUCLEIN AGGREGATION (57) Abstract Parkinson's disease (PD) is a neurodegenerative disorder which is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major component of which are filaments consisting of α -synuclein. The present invention provides α -synuclein mutations which accelerate α -synuclein aggregation and can thus be utilized for transgenic animal production and generation of the first progressive PD model. Also provided is an <i>in vitro</i> aggregation assay which can be utilized to identify α -synuclein nucleation inhibitors for the treatment of PD.		

*(Referred to in PCT Gazette No. 34/2000, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/22302

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/47 G01N33/50 A01K67/027 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K A01K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 06407 A (SAITOH TSUNAO ;MASLIAH ELIEZER (US); UNIV CALIFORNIA (US)) 9 March 1995 (1995-03-09) abstract examples 1-16 seq. ID 2 claims 1-92 ---	1,2,4-6
A	POLYMERPOULOS M H ET AL: "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE., vol. 276, 27 June 1997 (1997-06-27), pages 2045-2047, XP002083895 ISSN: 0036-8075 ---	1,2,4-6
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

9 February 2000

Date of mailing of the international search report

24.07.00

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Galli, I

INTERNATIONAL SEARCH REPORT

International Application No

PC. JS 99/22302

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PAIK S.R. ET AL.: "Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of C-terminal A beta fragment (residues 25-35)"</p> <p>FEBS LETTERS, vol. 421, no. 1, 2 January 1998 (1998-01-02), pages 73-76, XP002130118 the whole document</p>	1,2,4-6
A	<p>SPILLANTINI ET AL: "alpha synuclein in Lewy bodies"</p> <p>NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 388, 28 August 1997 (1997-08-28), pages 839-840, XP002090996 ISSN: 0028-0836 cited in the application the whole document</p>	1,2,4-6
A	<p>GOEDERT M: "The awakening of alpha-synuclein"</p> <p>NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 388, 17 July 1997 (1997-07-17), pages 232-233, XP002083894 ISSN: 0028-0836</p>	1,2,4-6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/22302

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 7 is directed to a method of treatment of the human/animal body: a search can be performed only based on the alleged effects of the compound/composition, if described.
2. ☒ Claims Nos.: 7
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Claims 1, 2, 4 completely, Claims 5 - 7 partially.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Claims Nos.: 7

Claim 7 refers to agents affecting nucleation of alpha-synuclein without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claim is ambiguous and vague, and its subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be performed for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: (1,2,4) - completely; (5-7) - partially

An isolated artificial alpha-synuclein mutant polypeptide which demonstrates accelerated aggregation to naturally occurring alpha-synuclein mutant polypeptides.

Said mutant being represented by seq. IDs 2,3 and 4.

A transgenic non-human animal engineered to express said polypeptide in the brain.

A method in which said polypeptide is used to screen for alpha-synuclein nucleation inhibitors.

2. Claims: (3) - completely

An in vitro aggregation assay for evaluating alpha-synuclein mutants which demonstrate accelerated aggregation.

3. Claims: (5-7) - partially

A method in which alpha-synuclein or aggregation-competent fragments thereof are used to screen for alpha-synuclein nucleation inhibitors.

* * * * *
 * * * * *

PC., JS 99/22302

Form PCT/ISA/210 (patent family annex) (July 1992)